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ORIGINAL ARTICLE: CLINICAL
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ABSTRACT
The safety profile of lenalidomide use in lower-risk myelodysplastic syndromes (MDS) patients
with del(5q) is well-established, but less is known in non-del(5q) patients. We provide safety data
from a randomized, phase 3 trial evaluating lenalidomide in 239 patients with lower-risk non-
del(5q) MDS ineligible/refractory to erythropoiesis-stimulating agents (ESAs). Compared with pla-
cebo, lenalidomide was associated with a higher incidence of grade 3–4 treatment-emergent
adverse events (TEAEs; 86% vs. 44%), but not risk of infection (p¼ .817) or hemorrhagic events
(p¼ 1.000). Grade 3–4 non-hematologic TEAEs were rare (the incidence of grade 3–4 pneumonia,
e.g. was 5.6% in the lenalidomide group and 2.5% in the placebo group). Common grade 1–2
non-hematologic TEAEs did not require dose modifications or treatment discontinuation. Acute
myeloid leukemia and second primary malignancies incidence was similar across treatment
groups. Lenalidomide had a predictable and manageable safety profile in lower-risk non-del(5q)
MDS patients ineligible/refractory to ESAs. Guidance on managing lenalidomide-related TEAEs is
provided to help maintain patients on therapy to achieve maximum clinical benefit.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01029262
ARTICLE HISTORY
Received 16 October 2017
Revised 11 December 2017







Myelodysplastic syndromes (MDS) represent a hetero-
geneous group of bone marrow failure disorders. The
disease course in MDS varies widely, and outcomes of
individual patients can be estimated using risk stratifi-
cation scores such as the International Prognostic
Scoring System (IPSS) [1] and the revised IPSS [2].
Patients with higher-risk disease have relatively short
survival, whereas those with lower-risk disease have
longer survival but face poor quality of life due to
cytopenias [3,4]. Anemia remains the main therapeutic
challenge in most patients with lower-risk MDS [3].
Lenalidomide is approved for the treatment of patients
who have transfusion-dependent anemia due to IPSS
lower-risk MDS associated with a deletion 5q cytogen-
etic abnormality (del[5q]). In this subgroup, lenalido-
mide yields red blood cell (RBC) transfusion
independence (RBC-TI) in 56–67% of patients [5,6].
For patients without del(5q), the first line of therapy is
erythropoiesis-stimulating agents (ESAs), with or without
granulocyte colony-stimulating factor; however, ESA
therapy is rarely effective if serum erythropoietin (EPO)
levels exceed 500mU/ml [7,8]. For patients who are ineli-
gible for or become refractory to ESAs, treatment options
are very limited [8] and outcomes are relatively poor [9].
Recently, the efficacy and safety of lenalidomide
were evaluated in patients with RBC transfusion-
dependent (RBC-TD), lower-risk, non-del(5q) MDS who
were ineligible for or refractory to ESAs [10]. In this
phase 3, randomized, placebo-controlled, double-blind,
multicenter study (MDS-005), a statistically significant
and clinically relevant proportion of lenalidomide-
treated patients achieved RBC-TI lasting 8 weeks
compared with placebo (26.9% vs. 2.5%, respectively;
p< .001). Patients with serum EPO levels at screening
500mU/ml were more likely to achieve RBC-TI 8
weeks than patients with EPO levels >500mU/ml.
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The primary type of adverse event (AE) associated
with lenalidomide is myelosuppression, including neu-
tropenia and thrombocytopenia [5,10]. Among patients
with del(5q) MDS, a reduction in neutrophil or platelet
count has been associated with a higher likelihood of
achieving RTC-TI, suggesting that lenalidomide-
induced cytopenias may be a surrogate marker of clo-
nal suppression [11].
Here, we characterize the safety profile of lenalido-
mide in patients with non-del(5q) MDS based on data
from the phase 3 MDS-005 trial and provide recom-
mendations for the effective management of treat-
ment-emergent adverse events (TEAEs).
Methods
Trial design
Full details of patient eligibility criteria and study
design have been described previously [10]. Briefly,
RBC-TD patients with IPSS low- or intermediate-1-risk
MDS without del(5q) who were ineligible for or refrac-
tory to ESAs were centrally randomized (2:1) to lenali-
domide 10mg once daily or matching placebo in 28-d
cycles (Figure 1). Patients with creatinine clearance
40–60ml/min received lenalidomide 5mg once daily.
Patients who achieved RBC-TI 8 weeks or erythroid
response [12] by week 24 continued treatment until
erythroid relapse, disease progression, unacceptable
toxicity, or consent withdrawal. The study was
approved by individual Institutional Review Boards of
participating centers and conducted according to the
Declaration of Helsinki. Written informed consent was
obtained from all patients before enrollment.
Safety assessment and statistical methods
Safety was a prespecified endpoint of the MDS-005
study [10]. Data for all patients who received at least
one dose of any study drug were included in the
safety analysis. Additional methods are described in
further detail in the online supplement.
Results
Baseline patient characteristics
A total of 239 patients were randomized; 160 received
lenalidomide and 79 received placebo. Baseline charac-
teristics for patients who received one or more study
doses (safety population) are presented
(Supplementary Table S1). Baseline characteristics were
generally comparable across treatment groups. Overall,
67.8% were male, 61.5% had serum EPO levels
500mU/ml, and 70.3% had 15% ring sideroblasts.
The median age was 71 years in the lenalidomide
group and 70 years in the placebo group.
Approximately, 79% of patients had received prior ESA
therapy.
Incidence of TEAEs
The median duration of treatment exposure was 164 d
(range 7.0–1158.0) for patients in the lenalidomide
group and 168 d (range 14.0–449.0) for patients in the
placebo group. Grade 1–2 TEAEs were reported in
96.9% of patients in the lenalidomide group and
92.4% in the placebo group (Supplementary Table S2).
The most common grade 1–2 TEAEs in the
Figure 1. MDS-005 study design. AML: acute myeloid leukemia; ESA: erythropoiesis-stimulating agent; EPO: erythropoietin; Int:
intermediate; IPSS: International Prognostic Scoring System; LEN: lenalidomide; MDS: myelodysplastic syndromes; q.d.: once daily;
RBC-TD: red blood cell transfusion-dependent; RBC-TI: red blood cell transfusion-independence; rhEPO: recombinant human EPO;
SPM: second primary malignancy. Defined as an average transfusion requirement of 2 units packed RBCs/28 d and no 8 con-
secutive weeks without RBC transfusions within the 16 weeks immediately prior to randomization. †Defined as RBC-TD despite
ESA treatment of 40,000 units/week rhEPO for 8 weeks or equivalent dose of darbepoetin, or serum EPO >500mU/ml without
prior ESA treatment. ‡LEN 5mg for patients with creatinine clearance 40–60ml/min.
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lenalidomide group were diarrhea (42.5% vs. 22.8% in
the placebo group), constipation (22.5% vs. 10.1%),
asthenia (21.9% vs. 16.5%), rash (21.3% vs. 5.1%), per-
ipheral edema (20.6% vs. 17.7%), and fatigue (20.6%
vs. 11.4%; Figure 2(A)).
Grade 3–4 TEAEs were reported in 86.3% of patients
in the lenalidomide group and in 44.3% of patients in
the placebo group (Supplementary Table S3). The
most common grade 3–4 TEAEs in the lenalidomide
group were neutropenia (61.9% vs. 11.4% in the pla-
cebo group) and thrombocytopenia (35.6% vs. 3.8%;
Figure 2(B)). When these events were analyzed accord-
ing to first onset during cycles 1–7, the per-cycle inci-
dence in the lenalidomide group ranged from 13.3%
to 32.9% for grade 3–4 neutropenia (Figure 3(A)), and
from 4.9% to 15.7% for grade 3–4 thrombocytopenia
(Figure 3(B)). The incidence of grade 3–4 neutropenia
peaked during cycle 3 (32.9%) and decreased there-
after (Figure 3(A)), whereas the incidence of grade 3–4
thrombocytopenia peaked during cycle 2 (15.7%) and
decreased thereafter (Figure 3(B)). The median time to
first occurrence of neutropenia (any grade) was 57 d
(range 1–541) and 29 d (range 1–169) for patients in
the lenalidomide and placebo groups, respectively
(data not shown). The median time to first occurrence
of thrombocytopenia (any grade) was 49 d (range
1–543) and 69 d (range 26–182), respectively.
The incidence of grade 3–4 pneumonia was 5.6% in
the lenalidomide group and 2.5% in the placebo
group (p¼ .35; Supplementary Table S3). Overall rates
of infection were similar between the lenalidomide
and placebo arms: 83 of 160 patients (51.9%) and 34
of 79 patients (43.0%) experienced infections in the
lenalidomide and placebo arms, respectively. In
patients who developed neutropenia (any grade), no
significant difference was seen in the incidence of
infection between the lenalidomide and placebo
groups (30.5% vs. 25.9%; p¼ .817; data not shown).
Figure 2. Most commonly occurring TEAEs according to randomized treatment group. (A) Grade 1–2 AEs in 20% of lenalido-
mide-treated patients. (B) Grade 3–4 TEAEs in 5% of lenalidomide-treated patients. LEN: lenalidomide; TEAE: treatment-emergent
adverse event.
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Similarly, rates of infection in patients without neutro-
penia did not differ significantly between treatment
groups (56.3% vs. 40.4%; p¼ .182). Overall, 33 of 160
patients (20.6%) and 8 of 79 patients (10.1%) experi-
enced hemorrhage in the lenalidomide and placebo
arms, respectively. In patients with thrombocytopenia
(any grade), the frequency of hemorrhagic events did
not significantly differ between the lenalidomide and
placebo groups (22.4% vs. 14.3%, respectively; p¼ 1.
000); similar results were seen in patients without
thrombocytopenia (12.9% vs. 9.7%, respectively;
p¼ .627).
Grade 3–4 deep-vein thrombosis (DVT) was
reported in three patients (1.9%) in the lenalidomide
group; no DVT was reported in the placebo group
(Supplementary Table S3). Four patients in the lenali-
domide group had an increase in serum creatinine,
and there was one case each of acute renal failure,
chronic renal failure, and renal impairment; no renal-
related TEAEs were reported in the placebo group.
There was no difference in the incidence of AML or
second primary malignancies (SPMs) between treat-
ment groups, although assessing the number of
events was limited by the relatively short follow-up
time for this analysis. With a follow-up of 261.5 per-
son-years in the lenalidomide group and 121.8 person-
years in the placebo group, the incidence of AML
progression was 1.91 per 100 person-years (95% confi-
dence interval [CI], 0.80–4.59) and 2.46 per 100
person-years (95% CI, 0.79–7.64), respectively (data not
shown). With a median follow-up duration for SPM
assessment of 2.0 years (range 0.2–3.6) in the lenalido-
mide group and 1.9 years (range 0.1–4.0) in the pla-
cebo group, the incidence of SPM was 3.8% for both
groups. In the lenalidomide group, reported SPMs
included T-cell chronic lymphocytic leukemia, adeno-
carcinoma of the colon, invasive ductal breast carcin-
oma, lung squamous cell carcinoma stage IV,
squamous cell carcinoma of the tongue, and basal cell
carcinoma (n¼ 1 for each event). In the placebo
group, reported SPMs included prostate cancer, squa-
mous cell carcinoma of the lung, and transitional cell
carcinoma (n¼ 1 for each event).
Grade 5 TEAEs occurred in four patients (2.5%) in
the lenalidomide group and in two patients (2.5%) in
the placebo group. Treatment-emergent deaths in the
lenalidomide group were due to neutropenic sepsis
(n¼ 1), myocardial infarction (n¼ 1), staphylococcal
infection and MDS progression (n¼ 1), and multi-organ
failure and bronchopulmonary aspergillosis (n¼ 1).
Treatment-emergent deaths in the placebo group
were due to pneumonia (n¼ 1) and pulmonary edema
and acute myocardial infarction (n¼ 1).
Impact of TEAEs on patient management
The proportion of patients who experienced TEAEs
that led to dose interruption, dose reduction, or
Figure 3. Incidence of new-onset grade 3–4 hematologic TEAEs by treatment cycle. (A) Neutropenia. (B) Thrombocytopenia. LEN:
lenalidomide; TEAE: treatment-emergent adverse event.
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treatment discontinuation is presented (Table 1).
Compared with patients in the placebo group, those
in the lenalidomide group were more likely to experi-
ence TEAEs requiring dose interruption (54.4% vs.
13.9%), dose reduction (6.3% vs. 1.3%), and treatment
discontinuation (31.9% vs. 11.4%). The incidence of
TEAEs that required dose interruption and subsequent
dose reduction was also higher in the lenalidomide
group (42.5%) versus 6.3% in the placebo group. The
median time to first dose interruption or reduction
due to TEAEs was 57 d (range 6–504) in the lenalido-
mide group (n¼ 73) and 22 d (range 16–44) in the pla-
cebo group (n¼ 5; data not shown). The median
duration of first dose interruption due to TEAEs was
14.5 d (range 1–80) in lenalidomide-treated patients
(n¼ 68) and 6 d (range 5–7) in patients receiving pla-
cebo (n¼ 4). The median time to treatment discontinu-
ation due to grade 3–4 TEAEs was 60 d (range 8–618)
in the lenalidomide group (n¼ 41) and 85 d (range
37–148) in the placebo group (n¼ 6).
The proportion of patients experiencing TEAEs that
led to hospitalization was 35.6% in the lenalidomide
group and 17.7% in the placebo group (data not
shown). The median duration of hospitalization due to
a TEAE was 11 d (range 1–76) and 9 d (range 1–66) in
the lenalidomide and placebo groups, respectively.
The most common reasons for hospitalization due to
TEAEs in the lenalidomide group were pneumonia
(5.6% vs. 2.5% in the placebo group), anemia (2.5% vs.
0%), neutropenic sepsis (1.9% vs. 1.3%), pleural effu-
sion (1.9% vs. 0%), and cardiac failure (1.9% vs. 1.3%).
The most common TEAEs requiring treatment modi-
fications in the lenalidomide group were neutropenia
and thrombocytopenia (Table 1). Neutropenia led to
dose interruption in 28.8% of patients, interruption
with subsequent dose reduction in 25.0% of patients,
and lenalidomide discontinuation in 4.4% of patients.
Thrombocytopenia led to dose interruption in 19.4%
of patients, interruption with subsequent dose reduc-
tion in 16.3% of patients, and lenalidomide discontinu-
ation in 8.8% of patients. In addition, one patient in
the lenalidomide group discontinued treatment
because of leukopenia and another discontinued treat-
ment because of anemia (data not shown).
Among patients treated with lenalidomide, the inci-
dence of grade 3–4 thrombocytopenia was similar in
responders (n¼ 43) and non-responders (n¼ 117; 35%
vs. 36%, respectively), as was the incidence of grade
3–4 anemia (5% vs. 6%, respectively; data not shown).
However, compared with non-responders, more res-
ponders developed grade 3–4 neutropenia (81% vs.
55%) and grade 3–4 leukopenia (23% vs. 7%,
respectively).
Non-hematologic TEAEs that led to treatment inter-
ruption and subsequent dose reduction were uncom-
mon in the lenalidomide group (Table 1); these TEAEs
included pruritus (0.6%) and rash (1.9%). Although
diarrhea was common (42.5% of patients had grade
1–2 diarrhea; Supplementary Table S2), it did not
require lenalidomide discontinuation in any patient;
some cases were managed by dose interruption
(n¼ 1) or interruption followed by dose reduction
(n¼ 2). Few patients discontinued lenalidomide
because of non-hematologic TEAEs; TEAEs of interest
requiring discontinuation included DVT (1.9%), pneu-
monia (1.3%), and rash (0.6%).
Discussion
The results of this analysis confirm that AEs associated
with lenalidomide treatment are predictable and man-
ageable in patients with lower-risk non-del(5q) MDS.
These results were comparable to the safety data of
lenalidomide, with no new safety concerns raised
[5,6,13]. The most common grade 3–4 TEAEs were neu-
tropenia and thrombocytopenia, which is consistent
with the known safety profile of lenalidomide in
lower-risk MDS [5,6,13]. These events tended to occur
early in the treatment course (i.e. within the first two
to three cycles) and, in most cases, were successfully
managed with dose interruptions and/or reductions,
avoiding the need for treatment discontinuation.
Diarrhea was the most common grade 1–2 TEAE, and
Table 1. Most common TEAEs requiring dose interruption,






TEAEs requiring dose interruption in 10% of patients, n (%)
Any TEAE 87 (54.4) 11 (13.9)
Neutropenia 46 (28.8) 2 (2.5)
Thrombocytopenia 31 (19.4) 2 (2.5)
TEAEs requiring dose reduction in 1.5% of patients, n (%)
Any TEAE 10 (6.3) 1 (1.3)
Neutropenia 5 (3.1) 1 (1.3)
TEAEs requiring dose interruption with subsequent reduction in 1.5% of
patients, n (%)
Any TEAE 68 (42.5) 5 (6.3)
Neutropenia 40 (25.0) 2 (2.5)
Thrombocytopenia 26 (16.3) 0
Pruritus 1 (0.6) 2 (2.5)
Constipation 0 2 (2.5)
Rash 3 (1.9) 0
TEAEs requiring treatment discontinuation in 1.5% of patients, n (%)
Any TEAE 51 (31.9) 9 (11.4)
Thrombocytopenia 14 (8.8) 0
Neutropenia 7 (4.4) 2 (2.5)
AMLa 0 2 (2.5)
Deep-vein thrombosis 3 (1.9) 0
AML: acute myeloid leukemia; TEAE: treatment-emergent adverse event.
aIn the short follow-up period, no increased incidence of AML or second
primary malignancies was observed.
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grade 1–2 TEAEs generally did not require dose reduc-
tion or discontinuation.
Other studies have also indicated that neutropenia
and thrombocytopenia are the two most common
grade 3–4 TEAEs in patients with lower-risk non-
del(5q) MDS treated with lenalidomide [14–16]. Rates
of grade 3–4 neutropenia were higher among lenalido-
mide-treated patients in this study when compared
with lenalidomide-treated patients in the earlier study
by Raza et al. [14]. Studies evaluating the administra-
tion of lenalidomide on days 1–21 of each 28-d cycle
generally report lower rates of severe myelosuppres-
sion, although Raza et al. [14] found little difference
between a 21-d dosing schedule and continuous dos-
ing (days 1–28) with regard to the incidence of grade
3–4 neutropenia (23% vs. 27%, respectively) or
thrombocytopenia (18% vs. 22%, respectively). Rates of
grade 3–4 non-hematologic TEAEs are consistently low
across studies. Concomitant use of lenalidomide and
ESAs does not appear to increase the incidence or
severity of lenalidomide-related TEAEs [15,16], and this
approach has been added to the updated National
Comprehensive Cancer Network guidelines as a treat-
ment option for patients with lower-risk non-del(5q)
MDS who fail to respond or stop responding to
ESAs [8].
The AE profile of lenalidomide in patients with non-
del(5q) MDS is also consistent with data in patients
with del(5q) MDS [5,6]. In a retrospective analysis of
pooled data from seven clinical studies of lenalido-
mide in non-del(5q) (n¼ 416) and del(5q) (n¼ 243)
MDS, neutropenia and thrombocytopenia were the
most commonly reported TEAEs. The frequency of
these events was lower in patients with non-del(5q)
Figure 4. Recommended dose modifications for grade 3–4 neutropenia. (A) First episode. (B) Subsequent episode. ANC: absolute
neutrophil count; CrCl: creatinine clearance; LEN: lenalidomide.
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than patients with del(5q) (45% vs. 72%, respectively,
for grade 3–4 neutropenia and 31% vs. 53%, respect-
ively, for grade 3–4 thrombocytopenia) [17].
Our findings also highlight the importance of fre-
quent monitoring, particularly during the first cycles of
therapy. Grade 3–4 neutropenia and thrombocytopenia
tended to occur early in the course of treatment, which is
consistent with previous experience of lenalidomide in
patients with del(5q) MDS [5,6]. Weekly monitoring,
including complete blood counts, has been recom-
mended for at least the first 2 months of lenalidomide
therapy; thereafter, biweekly or monthly monitoring may
be considered, depending on hematologic status [18].
In the MDS-005 study, lenalidomide resulted in
RBC-TI 8 weeks in 27% of patients who were ineli-
gible for or refractory to ESAs, and achievement of
RBC-TI 8 weeks was associated with significant
improvements in health-related quality of life in this
population [10]. These potential benefits underscore
the importance of effective management of TEAEs so
that patients may continue to receive therapy.
Recommended strategies for managing neutropenia
and thrombocytopenia have been formulated, with an
emphasis on using dose interruptions and reductions
to avoid discontinuing treatment whenever possible
(Figures 4 and 5). The ability to continue therapy in
responding patients is particularly important in this
population, given the limited treatment alternatives
that are available [8].
Median time to onset of RBC-TI 8 weeks with
lenalidomide was 10.1 weeks in the MDS-005 study,
with 90% of responses achieved within four cycles of
treatment [10], which is potentially longer than the
time to response reported for patients with del(5q)
MDS [5,6]. Based on this observation, the duration of
lenalidomide treatment in non-responding patients
can be limited to four to six treatment cycles.
Discontinuation within this timeframe should be
Figure 5. Recommended dose modifications for grade 3–4 thrombocytopenia. (A) First episode. (B) Subsequent episode. CrCl: cre-
atinine clearance; LEN: lenalidomide.
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avoided to ensure that patients are given the max-
imum opportunity to respond.
Optimal drug exposure by maintaining the highest
possible dose and minimizing the time off therapy
may also be important to patient outcomes. In a post
hoc analysis of the MDS-005 study, patients under-
going lenalidomide dose reductions had a longer dur-
ation of treatment, received a higher overall
lenalidomide dose, and were more likely to achieve
RBC-TI and clinical benefit [19]. These data are consist-
ent with previous findings in patients with del(5q)
MDS, showing that lenalidomide dose reductions are
significantly associated with improved AML-free sur-
vival and overall survival [20].
Rates of hematologic TEAEs were generally similar
in responding and non-responding patients treated
with lenalidomide, aside from grade 3–4 neutropenia,
which was higher in responders (81% vs. 55%). In a
previous analysis of data from two phase 2 trials of
lenalidomide in patients with lower-risk MDS, a reduc-
tion in platelet or neutrophil count was associated
with achievement of RBC-TI in patients with del(5q)
MDS, but not in those with non-del(5q) MDS [11].
Similarly, myelosuppression in MDS-005 did not pre-
dict response to lenalidomide (data not shown). These
findings suggest that in patients with del(5q) MDS,
lenalidomide directly suppresses the del(5q) clone, and
lenalidomide-related cytopenias may act as a surrogate
marker of clonal suppression. In patients with non-
del(5q) MDS, however, cytopenias may not be a reli-
able predictor of response, as the activity of lenalido-
mide may be due to its other effects on MDS clones
and the tumor microenvironment [11,14].
One limitation of this analysis is the relatively short
follow-up time. Although there were no major differ-
ences in incidence rates for AML between treatment
groups, only a small number of AML events were
reported. Similarly, the incidence of SPMs was the
same in both the lenalidomide and placebo groups
(3.8%). Additional analyses with longer follow-up may
be needed to better characterize the long-term safety
profile of lenalidomide in patients with non-del(5q)
MDS. A second limitation is that patients who could
not tolerate lenalidomide 2.5mg every other day on a
28-d schedule were discontinued from the study, as the
trial protocol did not include lower dosages. Further
research is needed to determine whether lower doses
are better tolerated and effective in this setting.
Conclusions
The MDS-005 study demonstrated that lenalidomide is
active in patients with lower-risk non-del(5q) MDS who
are ineligible for or refractory to ESAs [10]. For clini-
cians considering lenalidomide as a treatment option
for these patients (or for the subgroup of patients with
endogenous EPO levels500mU/ml who are more likely
to respond), it is important to be aware of the safety pro-
file of lenalidomide in this setting. The data reported
here suggest that lenalidomide has a predictable and
manageable safety profile in patients with lower-risk
non-del(5q) MDS who are ineligible for or refractory to
ESAs. TEAEs were common but infrequently necessitated
treatment discontinuation. Effective management of
TEAEs, particularly neutropenia and thrombocytopenia
using dose interruptions or reductions, can help patients
continue to receive lenalidomide therapy in order to
derive maximum clinical benefit.
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